Ads
related to: fasenra asthma medication dosage information- Dosing & Administration
View Dosing & Administration Info
For A Severe Asthma Medication.
- Eosinophilic Asthma Info
Read About A Treatment For Severe
Eosinophilic Asthma To Learn More.
- Eosinophil Diseases
Learn About A Treatment For
Multiple Eosinophil-Driven Diseases
- Adverse Reaction Info
Explore Safety Information For
A Severe Asthma Treatment.
- Prescribing Information
Get Prescribing Information For A
Severe Eosinophilic Asthma Therapy.
- Right For Your Patients?
Patient Profiles & Data Are Ready.
See If This SEA Tx Is A Good Fit.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor . It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca. [3] [4] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
This is because inhaling these drugs allows them to directly interact with your airways (as opposed to going into your bloodstream) while requiring a much smaller dosage and therefore potentially ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
Ads
related to: fasenra asthma medication dosage information